Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946825 · ClinicalTrials.gov registry record · Phase 2
Quit Smoking Study for People Who Use E-Cigarettes
A Phase 2 study of Nicotine Addiction and E-Cig Use, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
- 1
- Study location
NCT04946825: Completed Phase 2 study of Nicotine Addiction and E-Cig Use, sponsored by University of Vermont.
NCT04946825 is a Phase 2 study of Nicotine Addiction and E-Cig Use that has completed, run by University of Vermont. The registered enrollment target is 396 participants, below the 685-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04946825, a Phase 2 study of Nicotine Addiction and E-Cig Use, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching aim of this proposed randomized controlled trial (RCT) is to test nicotine replacement therapy (NRT) with text message support for two smoking cessation approaches among young adult dual users of combustible cigarettes (CC) and electronic cigarettes (EC). The investigators will use a 2x2 factorial design to randomize 390 participants to receive A) NRT plus text messages to quit CCs only, B) NRT plus text messages to quit CCs and ECs simultaneously, C) text messages alone to quit CCs only, or D) text messages alone to quit CCs and ECs simultaneously. The investigators primary outcome will be 7-day point-prevalence abstinence at the end of treatment (i.e., 3 months after randomization). The investigators will recruit participants using national advertising strategies. All treatment will be provided remotely in order to increase treatment access and comply with current COVID-19 restrictions.
Primary Outcome
The investigators will report breath carbon monoxide (CO; \<6 ppm) confirmed 7-day point-prevalence abstinence from combustible cigarettes at the end of treatment.
Conditions Studied
Interventions
- DRUG Nicotine replacement therapy patch
- DRUG Nicotine replacement therapy lozenge
- BEHAVIORAL Quit electronic cigarettes
- BEHAVIORAL Continue electronic cigarettes
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2021-06-27 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 2 |
What the finished NCT04946825 record still lists
NCT04946825 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 685-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (42% lower).
The record links to 3 conditions, with Nicotine Addiction appearing as the primary indexed condition, and to 4 interventions - of which Nicotine replacement therapy patch is the first listed.
NCT04946825 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT04946825 about?
NCT04946825 is a clinical study titled "Quit Smoking Study for People Who Use E-Cigarettes". The overarching aim of this proposed randomized controlled trial (RCT) is to test nicotine replacement therapy (NRT) with text message support for two smoking cessation approaches among young adult dual users of combustible cigarettes (CC) and electronic cigarettes (EC). The investigators will use a...
What is the current status of trial NCT04946825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2021-06-27. Estimated completion is 2023-10-25.
What conditions does trial NCT04946825 study?
This clinical trial studies the following conditions: Nicotine Addiction, E-Cig Use, Quitting Smoking.
What interventions are being tested in trial NCT04946825?
The interventions under investigation include: Nicotine replacement therapy patch (DRUG), Nicotine replacement therapy lozenge (DRUG), Quit electronic cigarettes (BEHAVIORAL), Continue electronic cigarettes (BEHAVIORAL).
Who is sponsoring clinical trial NCT04946825?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04946825 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04946825's enrollment target sits among peer trials
396 3rd of 10 higher than 8 of 10 other Nicotine Addiction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Addiction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches
RECRUITING · NA
-
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
RECRUITING · Early Phase 1
-
CONNECT Cancer Survivors With Tobacco Treatment
RECRUITING · NA
-
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
RECRUITING · NA
-
Cognitive Training for Nicotine Dependence
COMPLETED · NA
-
Effects of Brief Training on Craving Regulation
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI